Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Related articles in Annals
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Leung, N.
space
  arrow  Griffin, M. D.
space
 arrow  PubMed                        
space

REPLY

Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy

right arrow Nelson Leung, MD; Sundararaman Swaminathan, MBBS; Iftikhar Ahmed, MD; James T. McCarthy, MD; Robert C. Albright, DO; Mark R. Pittelkow, MD; Noel M. Caplice, MD, PhD; and Matthew D. Griffin, MB BCh

6 February 2007 | Volume 146 Issue 3 | Page 230


IN RESPONSE:

We appreciate Dr. Hellman's interest and comments. We, too, have noted that nearly half of our patients with nephrogenic fibrosing dermopathy had gadolinium exposure before the development of their disease. However, a similar number of our 50 dialysis patients were also exposed to gadolinium—some exposed on several occasions—without any evidence of the condition. This seems to support our hypothesis that multiple factors are involved in the pathogenesis of nephrogenic fibrosing dermopathy. We are currently investigating the possible interaction between gadolinium and erythropoietin in this disease.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info

From Mayo Clinic College of Medicine, Rochester, Minnesota.

Potential Financial Conflicts of Interest: None disclosed.


Related articles in Annals:

Letters
Nephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy
Sundararaman Swaminathan, Iftikhar Ahmed, James T. McCarthy, Robert C. Albright, Mark R. Pittelkow, Noel M. Caplice, Matthew D. Griffin, AND Nelson Leung
Annals 2006 145: 234-235. [Full Text]  

Letters
Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy
Richard N. Hellman
Annals 2007 146: 229-230. [Full Text]  



This article has been cited by other articles:


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
S. Jimenez-Valero, R. Moreno, A. Sanchez-Recalde, G. Galeote, L. Calvo, A. Viana, E. Lopez de Sa, and J. Lopez-Sendon
Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 137 - 146.
[Abstract] [PDF]


Home page
NDT PlusHome page
H. Pieringer, S. Schumacher, B. Schmekal, T. Gitter, and G. Biesenbach
Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure
NDT Plus, June 1, 2008; 1(3): 193 - 194.
[Full Text] [PDF]


box Article
 arrow  Table of Contents                
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Related articles in Annals
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Leung, N.
space
  arrow  Griffin, M. D.
space
 arrow  PubMed                        
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online